Leitat supports the pharmaceutical, biotechnology and MedTech industries throughout the development of chemical, biological and natural compounds in preclinical research, from the initial discovery phase to proof-of-concept demonstration in animals.
The technological centre showcases prototypes for the detection of resistant infections, non-invasive diabetes monitoring, alternatives to animal testing and driver fitness assessment.
Leitat will participate in Biospain 2026, one of Europe’s leading events for the biotechnology industry, taking place from 29 September to 1 October at the Bilbao Exhibition Centre (BEC). From stand 085 (Hall 2), the technological centre will present its advanced applied R&D and technological development capabilities for the biotech and pharmaceutical ecosystem, addressing current challenges in human and animal health.
On this occasion, Leitat will present new therapeutic and diagnostic technologies in areas such as oncology, inflammation, autoimmune diseases and rare diseases, supporting biotechnology and pharmaceutical companies in the development of innovative solutions.
Cross-cutting innovation in healthcare: therapeutic platforms, rapid diagnostics and continuous monitoring
In the therapeutic field, Leitat has a comprehensive drug development preclinical platform incorporating tailored in vitro, ex vivo and in vivo models according to the needs and therapeutic indication under study, as well as advanced capabilities in antibody generation and engineering and the generation of organoids and organ-on-chip systems —such as Project OGYX (the microfluidic Organ-on-a-Chip or Organofluidyx platform that simulates human tissue physiology as a predictive alternative to animal testing)— for the highly precise modelling of tissues and pathological microenvironments, providing a flexible offering aimed at accelerating and optimising new therapeutic candidates.
In parallel, in the diagnostic and healthcare field, the organisation works on antibody development as technological tools for MedTech platforms and detection systems, together with the validation of biomarker signatures with diagnostic and predictive value for human and animal health.
These capabilities facilitate the identification of molecules of high clinical interest and the creation of high-value-added solutions, materialised in technological prototypes presented at Biospain, such as the Klebsiella Project (a Point-of-Care device based on an electrochemical immunosensor for the rapid detection of pathogens), the iDIABETES / Salivet Project (a health monitoring platform with a saliva glucometer and cloud-connected wearables using Deep Learning) and the PANACEA Project (a portable, non-invasive device for the detection of substances in saliva samples).
‘One-Stop Shop’: comprehensive capabilities for the full antibody development cycle
In this context, Leitat positions itself as a key strategic partner thanks to its ‘One-Stop Shop for Antibodies’ offering, a comprehensive service that centralises all stages of antibody development in a single environment. This offering covers everything from molecule generation and engineering to support for drug discovery and preclinical validation, facilitating both the creation of new therapeutic candidates and the supply of technological tools for detection systems and MedTech platforms. In this way, the organisation offers pharmaceutical and biotechnology companies a flexible and efficient solution to accelerate the transfer of innovations to the market under rigorous quality standards.
Quality assurance and regulatory rigour for medical device development
Leitat’s participation in Biospain follows an important recognition of its capabilities in the field of medical technology: obtaining the UNE-EN ISO 13485 certification, awarded by AENOR. This international standard establishes the requirements for a quality management system applied to medical devices and related services. In Leitat’s case, the certification covers the design and development of four key types of products and solutions for third parties:
- Electromedical equipment for diagnosis and therapeutic monitoring.
- Diagnostic support software for in vitro diagnostic devices.
- Instruments developed through additive manufacturing and 3D printing.
- Bioreceptors for in vitro diagnostics.
This certification provides the highest guarantees of quality, traceability and regulatory rigour, strengthening Leitat’s capacity to support its clients throughout all stages of the development of new medical solutions, from initial R&D to prototyping and industrialisation.
